Abstract: A novel cell line, HU-ATTAK, was established from the peripheral blood of a patient with adult T-cell leukemia by means of co-culture with human umbilical cord vein endothelial cells (HUVEC) in the presence of interleukin-2 and damnacanthal. Immunophenotypic and cytogenetic analyses showed that HU-ATTAK is originally derived from leukemic cells and maintains the typical features of adult T-cell leukemia-lymphoma (ATLL). The growth of HU-ATTAK depends on IL-2 and HUVEC. When IL-2 was removed from the culture, HU-ATTAK stopped growing and eventually died through apoptosis. On the other hand, when HUVEC was removed from the culture, HU-ATTAK ceased proliferation but survived for a period of over two weeks. A culture experiment using micropore membranes showed that attachment of HU-ATTAK to HUVEC is necessary for proliferation. Stimulation of the co-stimulatory molecule OX40 ligand, which is expressed on HUVEC, is also involved in HU-ATTAK growth because the anti-OX40 ligand antibody completely inhibited the growth. These findings suggest the importance of the microenvironment for the survival and proliferation of some cases of ATLL. The HU-ATTAK cell line may thus be useful for studying the growth mechanism of ATLL and might yield new insights into the pathogenesis of ATLL.
INTRODUCTION
Human T-cell leukemia virus type I (HTLV-I) [1] has been established as the causative agent of adult T-cell leukemia/lymphoma (ATLL) [2] , but the mechanisms of tumorigenesis other than HTLV-I infection have largely remained speculative [3] . Okamoto et al. reported that five independent steps are necessary for acquisition of the final ATLL phenotype as an invasive neoplasm [4] . To clarify the abnormality of genetic or epigenetic changes, molecular analyses of fresh leukemia, lymphoma, or tumor cells have been conducted. These studies include cytogenetic analysis [5] and chromosome or array comparative genomic hybridization (CGH) [6, 7] , as well as investigation of RNA expression [8] or genomic instability [9, 10] . However, it has been difficult to determine how such changes can contribute to tumorigenesis in ATLL. An in vitro culture system of ATLL may conserve such genetic changes involved in tumor development and thus yield some clues concerning the growth mechanism of ATLL. It is known that attempting to *Address correspondence to these authors at the (YK) Department of Hematology, Toyota Kosei Hospital, 500-1, Ibohara, Josui-cho, Toyota, 470-0396, Japan; Tel: (+81) -565-43-5000; Fax: (+81) -565-43-5100; Email: y-kagami@toyota.jaaikosei.or.jp and (MA) Division of Molecular Medicine, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan; Tel: (+81)-52-762-6111; Fax: (+81)-52-763-5233; E-mail: mseto@aichi-cc.jp grow tumor cells of ATLL patients is very difficult, and only a few cell lines have been established [11] [12] [13] [14] [15] [16] . Tumor cells of ATLL patients grow very vigorously in vivo, but differences between in vivo and in vitro proliferative features of ATLL have remained unclarified. We therefore examined the possibility of the stimulation of tumor cell growth by environmental factors which may work in vivo. We found that one approach for this purpose is the use of other kinds of cells as feeder cells. We previously reported that a human skin cancer cell line (HSC-I) supported growth of leukemic cells in some ATLL patients in the presence of IL-2, which then became HSC-I-dependent cell lines [14] . These cell lines would grow even though direct contact between the ATLL cell line and feeder cells was inhibited by a micropore membrane. However, the fact that some other ATLL patient cells would not grow under such conditions suggested the existence of other kinds of feeder cells. In the study presented here, we tried to establish ATLL cell lines using the human umbilical cord vein endothelial cell (HUVEC) as feeder cells, which expresses various adhesion molecules on its cell surface and exhibits the exocrine secretion of various cytokines. We succeeded in establishing a HUVECdependent cell line from among ten samples derived from peripheral blood or lymph node cells of ATLL cases. Analysis of factors derived from HUVEC indicated that the OX40 ligand was one of the growth factors of ATLL.
PATIENT AND METHODS

The Patient's Clinical Profile
The patient was a 61-year-old Japanese male who was admitted because of poor performance status. He had systemic lymphadenopathy, hepatosplenomegaly and generalized erythematous skin. Laboratory data indicated hypercalcemia, renal failure and positivity of anti-HTLV-I antibody. The peripheral blood white cell count was elevated and contained 61% of flower-like cells whose immunological phenotype was CD2(+), CD3(+), CD4(+), CD8(+), CD25(+), CD7(-) and CD19(-). From these clinical data, he was diagnosed with an acute type of ATLL. He received various combinations of chemotherapies, but had no remission and died. The peripheral mononuclear cells were frozen and preserved for the further analyses and the establishment of HUATAK.
Cell Culture
HUVEC was purchased from Lonza Walkersville, Inc. (Walkersville, MD, USA) and was maintained in EGM-2 medium with a Bullet Kit (CC-3162), which contains a growth supplement kit with hydrocortisone, hFGF-, VEGF, R3 IGF-1, ascorbic acid, heparin, FBS, hEGF and GA-1000 (Lonza Walkersville, Inc.).
ATLL cells were co-cultivated with HUVEC using Iscove's modified Dulbecco's medium (IMDM) containing 20% human plasma, 10 ng/ml of IL-2 (PeproTech), and 20 nM damnacanthal (Calbiochem, Merck, Tokyo, Japan).
The established cell line, HU-ATTAK will be deposited to Riken Bioresource Center for academic use.
(http://www.brc.riken.go.jp/lab/cell/english/).
Flow Cytometry
Surface immunophenotyping of the lymphoma, HU-ATTAK and HUVEC was performed using the following panel of lymphoid-associated monoclonal antibodies: HLA-DR (CR3/43), CD4 (RPA-T4), (DAKO Denmark), CD2 (RPA-2.10), CD3 (UCHT1), CD5 (L17F12), CD8 (SK1), CD10 (WM15), CD13 (WM15), CD14 (M5E2), CD19 (SJ25C1), CD20 (L27), CD25(M-A251), CD33 (P67.6), CD45 (2D1), CD56 (NKH-1), CD57 (NK-1), TCR (WT31), TCR (11F2), (BD Pharmingen, Japan BD, Tokyo, Japan), CD1a (BL6), CD7 (8H8.1), (Beckman Coulter, Inc. CA, USA), CD134(W4-3) and CD252(TAG-34) (Medical & Biological Laboratories, Nagoya, Japan). Multiparameter analysis of gated cell populations during cell suspension studies was used to yield more definitive immunophenotypic information (CELLQuest software, Becton-Dickinson, CA, USA).
Cytogenetics
Chromosomal analysis of the original leukemic cells and HU-ATTAK was performed at the Special Reference Laboratory (Tokyo, Japan). The analysis of HU-ATTAK was performed with conventional methods and karyotyped according to ISCN.
DNA Extraction and Southern Blot Analysis
For the extraction of high molecular weight DNA, the original bone marrow tumor and HU-ATTAK cells were treated with proteinase K and extracted with phenol and chloroform as described elsewhere [17] . Data of Southern blot analysis for the HTLV-I integration site were acquired from the Special Reference Laboratory.
Array CGH
DNA labelling, array fabrication, hybridization, normalization and analysis were performed as described previously [18] . The array CGH glasses used in the present study were ACC Version 5.0 [19] . The array consisted of 2304 BAC/PAC clones spotted in duplicate. These clones were from libraries RP11 and RP13 for BAC clones, and RP1, RP3, RP4 and RP5 for PAC clones. These clones were obtained from the BAC/PAC Resource Centre at the Children's Hospital, Oakland Research Institute, Oakland, CA, USA (http://bacpac.chori.org/). The BAC/PAC clones were aligned with each chromosome on the basis of data from Ensembl Genome Data Resources (release 40; http://www.ensembl.org/) or the National Centre for Biotechnology Information (Build 36; http://www. ncbi.nlm.nih.gov/ ). The locations of all the clones used for array CGH were confirmed by fluorescent in situ hybridization (FISH). Clones that showed unreliable data in 17 unrelated normal individuals were excluded from the data analysis. Clones of the sex chromosomes were also excluded. A total of 2125 clones (covering 2867 Mb, 1.34-Mb resolution) were further analyzed.
Thresholds for copy number gain and loss were determined so that the estimated false discovery rate (FDR) was approximately 0.05. The thresholds for gain and loss were +0.186868 and 0.144762, respectively. We defined the region of gains and losses as: (a) three contiguous clones showing gain (log2 ratio +0.19 to +1.0) or loss (log2 ratio 1.0 to 0.15); or (b) clones, if not contiguous, showing high copy number gain (log2 ratio> + 1.0) or homozygous loss (log2 ratio < 1.0).
IL-2 Dependency of HU-ATTAK
HUVEC were seeded in a 12-well cluster dish (Costar, Cambridge, MA, USA) on day -1. On day 0, after removal of the medium, 2 ml of a HU-ATTAK cell suspension at a concentration of 5 X 10 4 /ml was plated onto each well. Every 3 days, floating viable cells after pipetting were concentrated to 1 ml and the number of viable cells was counted. Then 10 5 HU-ATTAK cells were resuspended in 2 ml of fresh medium and seeded into new wells at a concentration of 5 X 10 4 /ml. For the IL-2-dependent growth assay, 10 5 HU-ATTAK cells were cultured in a 12-well cluster in the presence or absence of 10 ng/ml IL-2. The viable cells were counted after three days.
Dose Dependency of IL-2
Dose dependency of IL-2 was examined as follows: 5 X 10 3 HU-ATTAK cells in the presence of HUVEC were cultured in 2 ml of culture medium containing IL-2 in a 12-well cluster dish. The IL-2 was serially diluted from 270 ng/ml by one-thirds. After three days, 100 l of cell suspension from each well was transferred to a 96-well cluster dish. The number of viable cells was measured using a colorimetric assay (CellTiter 96TM; Aqueous NonRadioactive Cell Proliferation Assay Kit, Promega, Madison, WI, USA). The mean values of the absorbance at 490 nm in the quadruplicate wells were plotted as a growth curve.
Detection of Apoptotic Cells
10
5 HU-ATTAK cells were cultured on HUVEC with or without IL-2 for 2 days. These cells were washed and stained with FITC-labeled Annexin V (AN) and propidium iodide (PI) (Trevigen Inc., Gaithersburg, MD, USA). Early apoptotic cells which express phosphatidylserine on the outer cell membranes bind AN, and dead cells with a compromised cell membrane allow PI to bind to the cellular DNA. Using flow cytometric analysis, the degrees of apoptosis were measured with two populations of AN+/PI-(early apoptotic cells) and AN+/PI+ (late apoptotic cells and necrotic cells).
Transwell Culture Between HUVEC and HU-ATTAK
A Transwell culture was established using a 0.4-m pored bottom cup (Transwell® Costar, Cambridge, MA, USA). On day -1, HUVEC were seeded into a 6-well cluster dish (Costar). On day 0, 1.5 ml of the culture medium was replenished, the pored bottom cups were settled, and then 10 5 HU-ATTAK cell suspensions were inoculated. The number of viable cells was counted on days 3, 5 and 7.
Growth Inhibition by Anti-OX40 or Anti-OX40 Ligand Antibody
10
3 HUVEC/well were cultured in a 96-well cluster dish (Costar) on day -1. On day 0, after removal of the medium, 100 l of HU-ATTAK suspension at a concentration of 5 X 10 4 /ml was plated onto each well which contained various concentrations of monoclonal anti-OX40 or anti-OX40 ligand antibody in quadruplicates. Viable cell numbers of each cell suspension were counted every three days after pipetting. The cell density was maintained at 5 X 10 4 /ml, and 5 X 10 3 HU-ATTAK cells were seeded into a new well of a 96-well cluster dish containing precultured HUVEC. If the cell density was less than 5X10 4 /ml, the whole cell suspension was centrifuged and the medium was changed to a new medium, then seeded into a new well.
RESULTS
Establishment of HU-ATTAK
The peripheral mononuclear cells frozen prior to the start of chemotherapy, were thawed and cultured in IDMEM with 20% human plasma and 10 ng/ml of human IL-2 in the presence or absence of HUVEC. However, the cells did not grow for long under either condition. During the search for agents to stimulate the growth of T-cell lymphoma in vitro, we found that the addition of 20 nM damnacanthal to the medium stimulated the growth of leukemic cells for some ATLL cases in the presence of IL-2 (Fig. 1A) . We therefore added 20 nM damnacanthal to the IDMEM culture together with 20% human plasma and 10 ng/ml IL-2 without HUVEC. However, this condition did not support growth and the tumor cells ceased to grow. When HUVEC was added to this condition on September 2007, mononuclear cells kept growing vigorously for more than 4 months. Interestingly, after 4 months, the growth rate was identical whether damnacanthal was present or absent, although tumor cell growth was strictly dependent on the presence of IL-2 and HUVEC (Fig. 1B) . This cell line which continued to grow for 9 months from the start of culture was designated as HU-ATTAK. 
Phenotypic and Genotypic Analyses
The phenotypic analysis of the original leukemia and HU-ATTAK showed expression of CD3, CD4 and CD25, which are characteristic of ATLL. CD8 was positive in the original leukemic cells, but it became negative in the new cell line. The analyses of other phenotype of HU-ATTAK indicated that CD1(-), CD2(+), CD5(+), CD7(-), CD10(-), CD13(+/-), CD19(-), CD56(-), CD57(+/-), HLA-DR(+), Cell Number TCR-(-), and TCR-(-), which showed some aberrations from normal helper T-cells.
The proviral integration pattern of the original peripheral mononuclear cells and HU-ATTAK identified by means of Southern blot analysis showed that the clonal integration pattern of HTLV-I and the two flanking sequence bands were identical. However, the bands of the internal sequence of the gag-env gene were partially deleted in HU-ATTAK, which suggested that microdeletion occurred during establishment of the HU-ATTAK cell line ( Fig. 2A) .
Chromosomal analysis showed that the karyotype of the original leukemic cells was idic (18) (Fig. 2B) . The majority of these aberrations were conserved in HU-ATTAK. The results of these analyses proved that HU-ATTAK was derived from the original leukemic cells.
IL-2-Dependent Growth of HU-ATTAK Cells
After establishment of the HU-ATTAK cell line on HUVEC in the presence of IL-2, we examined to what extent this cell line depended for its growth on each of the factors. First, IL-2 was removed from the culture and as a consequence HU-ATTAK cells stopped growing, and almost all the cells died within three days even in the presence of HUVEC cells (Fig. 3A) . The cell death mechanism in the absence of IL-2 was examined with the Annexin V/PI staining method (Fig. 3B) . The cultured cells were stained with FITC-labeled annexin V and propidium iodide (PI) and analyzed using a FACS scan 24, 48 and 72 hours later. Annexin V positive apoptotic cells increased from 24 hours, which demonstrated the anti-apoptotic effect of IL-2.
The growth promotion by IL-2 was examined in the presence of serially diluted concentrations of IL-2, and dose dependence was observed for concentrations from 370 pg/ml to 30 ng/ml. The growth rate was less than twice that obtained with the minimum concentration, indicating that the growth promotion activity of IL-2 was weak (Fig. 3C) . These findings indicated that IL-2 had a potent anti-apoptotic effect and a weak growth promotion action.
HUVEC-Dependent Growth
Next, HUVEC cells were removed from the culture. Fig.  (4) shows the growth curve of HU-ATTAK cells in the presence of IL-2 but without HUVEC. In the culture without HUVEC, the growth rate was similar to that of the control culture for three days, after which proliferation stopped and the cells survived for 2 weeks. These findings indicated that HUVEC promoted the proliferation of HU-ATTAK in the presence of IL-2.
Direct Contact is Necessary for Growth of HU-ATTAK
We examined whether direct contact with HUVEC cells is required for HU-ATTAK to grow. HU-ATTAK was cultured in an inner cup separated from HUVEC cells by a 0.4-m microporous membrane to prevent direct cell-to-cell contact. In the absence of direct contact, HU-ATTAK stopped growing a few days later and finally died. These findings suggested that the molecule(s) expressed on the surface of HUVEC could sustain HU-ATTAK growth (Fig.  5) .
Growth Promotion of HUVEC is Derived from the OX40 Ligand
HUVEC expresses the OX40 ligand, which is a molecule that acts against ATLL cells by means of adhesion and antiapoptosis [20, 21] . OX40 ligand expression was limited to HUVEC while OX40 expression was limited to HU-ATTAK (Fig. 6A) . We examined the effect of the OX40 ligand on The numbers of viable cells in the three wells were counted on days 4, 7, 10, 13 and 16. This is a representative of two independent experiments. Cell numbers are plotted using a log scale.
HU-ATTAK growth by adding an antibody to the culture system. In the presence of the anti-OX40 ligand antibody, the growth of HU-ATTAK was inhibited to the same level as that in the culture without HUVEC (Fig. 6B) . On the other hand, the inhibitory effect was weak in the presence of the anti-OX40 antibody (Fig. 6C) . These findings indicated that growth promotion by HUVEC is dependent on its expression of the OX40 ligand.
DISCUSSION
The mechanism of tumor cell growth in ATLL has been unclear, and analysis of ATLL-derived cell lines is therefore important. However, it has been difficult to establish cell lines from original tumor cells. Most ATL-derived cell lines have been established in the presence of IL-2 [16] . Although various cytokines can transiently stimulate the growth of normal T-cells, proliferation of ATLL cells by IL-2 is limited in spite of high expression of the IL-2 receptor chain [22] . Establishment of an ATLL-derived cell line is therefore relatively rare. This difficulty may be explained by the presence of regulatory mechanisms other than IL-2 and/or factors supplementary to IL-2.
We hypothesized that tumor cell growth might be aided by environmental factors, including cytokines. Since one of the candidate factors is a cell-to-cell interaction between the cells in the microenvironment, we used HUVEC as feeder cells which might then function as alternatives for microenvironmental factors. Although HUVEC alone had no effect on the growth of ATLL, in combination with damnacanthal and IL-2 it could maintain the growth of ATLL cells for one in ten ATLL cases.
We have tried the kinase inhibitors genistein and damnacanthal, expecting that such inhibitors might affect cell growth signaling. Interestingly, damnacanthal had a stimulatory effect for this culture system. Damnacanthal is a tyrosine kinase inhibitor specific to p56 lck [23] and has a biological inhibitory effect on apoptosis induced by 14 kDa human immunodeficiency virus-1 viral protein R (Vpr) [24] . p56 lck is the signaling protein activated through the T-cell receptor and is phosphorylated by the activated IL-2 receptor chain [25, 26] . Although the detailed downstream signal transduction of p56 lck through IL-2 is unknown, dephosphorylation of p56 lck by damnacanthal may play a role in the establishment of HU-ATTAK in the early stage of the primary culture. The growth promotion effect of damnacanthal was not limited to ATLL cells because we could use damnacanthal to establish another IL-2-dependent cell line derived from T-cell lymphoma (manuscript in preparation).
In the study presented here, the growth promotion of HUVEC was proved to be mediated by the OX40-OX40 ligand system. ATLL cells frequently express OX40 molecules, which help ATLL cells attach to endothelial cells [20] . OX40 is a member of the TNF receptor family and its stimulation inhibits apoptosis of ATLL cells by FAS [21] or transfers the signals for the activation of NF-B [27] . The activation of NF-B is known to consistently persist in ATLL cells in vivo [28] , especially by means of the NF-B inducing kinase [29] . The activation of NF-B through OX40 may thus be related to the growth promotion of HU-ATTAK, which can be used as model system for functional studies of ATLL cells.
Our analysis of the growth mechanism of HU-ATTAK established that both growth promotion and inhibition of apoptosis depended on environmental factors. Since these mechanisms have been identified only in this cell line, it is necessary to clarify whether tumor cells of patients can grow in a similar environment in vivo. Although it has been HU-ATTAK cells in quadruplicate culture were cultured in the presence of 0 g/ml ( ), 1 g/ml ( ), 10 g/ml( ) and 30 g/ml( ) of OX40 ligand antibody. The negative control was the absence of HUVEC ( ). Cells were counted on days 3, 6 and 8. This is a representative of two independent experiments. Cell numbers are plotted using a log scale. (C) Anti-OX40 antibody partially inhibits the growth of HU-ATTAK. HU-ATTAK cells in quadruplicate culture were cultured in the presence of 0 g/ml ( ), 1 g/ml ( ), 10 g/ml ( ) and 30 g/ml ( ) of OX40 antibody. The negative control was without HUVEC ( ). Cells were counted on days 3, 6 and 8. This is a representative of two independent experiments. Cell numbers are plotted using a log scale. established that HTLV-I is the original causative agent of ATLL, the pathophysiological and clinical courses of this disease differ significantly. If interaction with the environment causes oncogenesis in the later stage of ATLL, analysis of the growth mechanism of HU-ATTAK may provide insights into the molecular pathogenesis of ATLL, and thus might yield new therapeutic strategies.
